Greenwich LifeSciences, Inc. (GLSI)

US — Healthcare Sector

Peers: RVPH EYEN IMMP AVXL VRPX ACXP MNOV NXTC ENTX XFOR TERN DAWN PDSB INZY AMLX ABOS

Automate Your Wheel Strategy on GLSI

With Tiblio's Option Bot, you can configure your own wheel strategy including GLSI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol GLSI
Rev/Share 0.0003
Book/Share 0.1927
PB 45.4681
Debt/Equity 0.0
CurrentRatio 2.6235
ROIC -5.3029

MktCap 117106308.0
FreeCF/Share -0.5525
PFCF -16.1158
PE -7.2974
Debt/Assets 0.0
DivYield 0
ROE -3.4114

Rating C-
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 3
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

GLSI
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms.

image for news Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

GLSI
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless …

image for news Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

GLSI
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data.

image for news Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

About Greenwich LifeSciences, Inc. (GLSI)

IPO Date 2020-09-25
Website https://greenwichlifesciences.com
Industry Biotechnology
CEO Mr. Snehal S. Patel
Employees 4

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.